FDC Q1 FY27: consol PAT +9% YoY to ₹132 Cr on margin gains; revenue growth slows to 3%
PAT +9.18% YoY · revenue +2.97% · margins expanding
₹667.69 Cr
+2.97% YoY
₹132.49 Cr
+9.18% YoY
18.52%
+0.8pp YoY
₹8.14
FDC Ltd's consolidated Q1 FY27 (quarter ended June 30, 2026) print is profit-led rather than volume-led: consolidated PAT rose 9.2% YoY to ₹132.49 Cr on revenue growth of just 3.0% YoY to ₹667.69 Cr, with net margin expanding to 18.52% from 17.74% a year ago. Operating margin (PBT before exceptional items, adjusted for finance cost, depreciation and other income, over revenue) held roughly flat at 21.42% versus 21.64% a year ago — so the earnings growth was driven mainly by a 34.2% YoY jump in other income (₹47.65 Cr vs ₹35.50 Cr) rather than by core operating leverage. Sequentially the quarter looks stronger, with PAT up 28.1% QoQ and revenue up 14.2% QoQ against a soft Q4 FY26, but per our reading convention that QoQ move is supporting detail, not the headline story.
Q1 FY-2027 vs prior quarters
Standalone growth diverges sharply from the consolidated picture: standalone revenue grew 20.8% YoY to ₹655.10 Cr against consolidated revenue growth of only 3.0% YoY, implying the net inter-company/subsidiary contribution — which the auditors describe as immaterial to the group this quarter at ₹17.21 Cr of pre-consolidation subsidiary revenue — was unusually elevated in the year-ago quarter. Readers comparing the standalone and consolidated releases should expect the topline growth rates to look very different this quarter for that reason; standalone PAT itself grew a similar 8.0% YoY to ₹132.02 Cr, in line with the consolidated PAT trend.
The stock went into the print at ₹408.95, down 4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
NPM expanded to 18.52% from 17.74% YoY (+0.78pp) and 16.29% QoQ (+2.23pp) — OPM ~21.42% vs 21.64% YoY (flat) and 18.19% QoQ (+3.23pp)
Consolidated EPS ₹8.14 vs ₹7.45 a year ago — standalone EPS ₹8.11 vs ₹7.51
No exceptional items in current or year-ago quarter — FY26's actuarial exceptional charge (₹20.79 Cr) and fair-value swing were confined to Q4 FY26
We have no analyst consensus estimates on record and a web search turned up no published Q1 FY27 preview or brokerage estimate for FDC specifically, so vsStreet is marked unknown rather than assumed. Similarly, there is no formal management guidance on record for this quarter — company records and search show none — so vsGuidance is also unknown. No separate management press release with qualitative commentary was available in the context to cross-check against the numbers; the filing itself is limited to the regulatory disclosure and financial statements.
W1
Whether the standalone-vs-consolidated revenue growth gap (+20.8% vs +3.0% YoY) normalizes or recurs in Q2 FY27
W2
Operating margin trajectory — flat YoY at ~21.4% while NPM-led earnings growth continues; watch if OPM itself expands in coming quarters
W3
Outcome of Maharashtra FDA's June 4, 2026 seizure of 'Enerzal' stock and samples — no quantified impact disclosed yet